Veru Inc. (NASDAQ:VERU) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET

Company Participants

Sam Fisch - Executive Director, Investor Relations & Corporate Communications

Mitchell Steiner - Chairman, Chief Executive Officer & President

Michele Greco - Chief Financial Officer & Chief Accounting Officer

Conference Call Participants

Yi Chen - H.C. Wainwright

Brandon Folkes - Cantor Fitzgerald

Operator

Good morning, ladies and gentlemen, and welcome to Veru Inc. Investor Conference Call. All participants will be in listen-only mode. [Operator Instructions] After this morning's discussion, there will be an opportunity to ask questions. Please note that this event is being recorded.

I would now like to turn the conference call over to Mr. Sam Fisch, Veru Inc.'s Executive Director, Investor Relations and Corporate Communications. Please go ahead.

Sam Fisch

Good morning. The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances, and development, and product portfolio.

Such forward-looking statements are subject to known and unknown risks and uncertainties and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our 10-Q and 10-K SEC filings, as well as in our press releases from time to time.

I would now like to turn the conference call over to Dr. Mitchell Steiner, Veru Inc's, Chairman, CEO, and President.

Mitchell Steiner

Good morning. With me on this morning's call are Dr. Gary Barnett, Chief Scientific Officer; Michele Greco, the CFO, CAO; Michael Purvis, EVP, General Counsel and Corporate Strategy; and Sam Fisch, Executive Director of Investor Relations and Corporate Communications. Thank you all for joining our call.

Veru Inc. is a late-stage clinical -- a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-Cov-2 and other viral acute respiratory distressed syndrome ARDS-related diseases. Our drug development program includes Enobosarm, a selective androgen receptor agonist for the management of advanced breast cancer; and sabizabulin, a microtubule disruptor for the treatment of the hospitalized COVID-19 and other viral-related ARDS.

The company also has an FDA-approved product, commercial products, the FC2 Female Condom, internal condom for dual protection against unplanned pregnancy and sexually transmitted infections. The revenue from the sexual health program is being used to partially fund the clinical development of our late-stage therapeutic candidates, which aim to address multibillion-dollar premium market opportunities.